弥漫大B细胞淋巴瘤患者血清β_2-MG、VEGF、bFGF、IL-6水平与国际预后指数的关系  

The relationships between the serum levels of β_2-MG,VEGF,bFGF,and IL-6 in patients with diffuse large B cell lymphoma and parameters of International Prognostic Index

作　　者：季冬梅[1] 洪小南[1] 曹军宁[1] 陆洪芬[2] 李秋[3] 吴向华[1] 

机构地区：[1]复旦大学附属肿瘤医院化疗科,上海200032 [2]复旦大学肿瘤学系 [3]四川大学华西医院肿瘤生物治疗国家重点实验室,成都610041

出　　处：《肿瘤》2007年第5期402-405,共4页Tumor

基　　金：中国临床肿瘤学基金资助项目(编号:Y-2004-0002)

摘　　要：目的:探讨弥漫大B细胞淋巴瘤(diffuse large B cell lymphoma,DLBCL)患者血清血管内皮生长因子(vascular endo-thelial growth factor,VEGF)、白介素-6(interleukin-6,IL-6)、碱性成纤维生长因子(basic fibroblast growth factor,bFGF)、β2微球蛋白(β2-microglobin,β2-MG)水平与国际预后指数(international prognostic index,IPI)之间的关系。方法:33例初治DLBCL患者按IPI评分分成低危组(IPI<2)和中高危组(IPI≥2),采用ELISA方法检测患者外周血血清中的VEGF、IL-6、bFGF水平,应用放射免疫分析法检测血清β2-MG水平。结果:高危组血清β2-MG、VEGF、bFGF、IL-6水平均较低危组明显升高。结论:血清β2-MG、VEGF、bFGF、IL-6水平可以和IPI一起用于DLBCL患者预后判断,为患者的个体化治疗以及设计新的临床试验提供依据。Objective ： This study aimed to determine the relationships between serum levels of vascular endothelial growth factor （VGEF） , interleukin-6 （IL-6） , basic fibroblast growth factor （bFGF） , β2-microglobin （β2-MG） and the parameters of International Prognostic Index （IPI） in patients with diffuse large B cell lymphoma （DLBCL）. Methods： Thirty three newly diagnosed DLBCL patients were divided into two groups： low risk group （IPI 〈 2） and moderate to high risk group （IPI ≥2 ）. Serum levels of VEGF, IL-6, and bFGF were measured by enzyme-linked immunosorbent assay. Radioimmunoassay was applied to detect the serum level of β2-MG. Results： Serum levels of β2-MG, VEGF, bFGF , and IL-6 were significantly elevated in the high risk group than those in the low risk group. Conclusions： The serum levels of β2-MG, VEGF, bFGF, and IL-6 combined with IPI can be used for evaluating the prognosis of DLBCL patients. Detection of these cytokines provides the clue for implementing appropriate therapeutic approaches for individual patients and designing new clinical trails.

关 键 词：淋巴瘤 非霍奇金 细胞因子类 国际预后指数 

分 类 号：R733.1[医药卫生—肿瘤]